The National Institute for Health and Care Excellence (NICE), has published final draft guidance recommending dupilumab as a ...
Sanofi and Regeneron’s Dupixent (dupilumab) has received positive final draft guidance from the National Institute for Health ...
Fewer than 1 in 5 patients with COPD receive the recommended levels of care, with nearly 1 in 4 waiting more than 5 years to be diagnosed, research has shown. The new research, from lung charity ...
In some patients with chronic obstructive pulmonary disease (COPD), type 2 inflammation may increase exacerbation risk and may be indicated by elevated blood eosinophil counts. Dupilumab, a fully ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results